4'-acetamidophenyl 4-guanidinobenzoate | 79126-29-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 英文名称: 4'-acetamidophenyl 4-guanidinobenzoate
• 英文别名: (4-acetamidophenyl) 4-(diaminomethylideneamino)benzoate
• CAS: 79126-29-7
• 化学式: C₁₆H₁₆N₄O₃
• 分子量: 312.328
• InChiKey: VACGBZYEDFQOIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Novel IGF-1 composition and its use
  申请人：Shirley A. Bret

  公开号：US20050266046A1

  公开（公告）日：2005-12-01

  A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided. The precipitated IGF-I syrup, IGF-I reconstituted from the IGF-I syrup, pharmaceutical compositions, and kits are useful in IGF-I therapy directed to IGF-I-responsive conditions.

  本研究提供了一种高浓度、低含盐、生物活性糖浆形式的 IGF-I 或其变体及其制备方法。这种新型 IGF-I 糖浆的 IGF-I 浓度至少约为 250 毫克/毫升，密度约为 1.0 克/毫升至约 1.2 克/毫升，粘度约为 13,000 厘泊（cps）至约 19,000 厘泊（在环境温度（23° C）下测量）。制备 IGF-I 糖浆的方法是从溶液中沉淀或分离 IGF-I，最好是调节溶液的 pH 值，或使用溶解度增强剂浓缩溶液中的 IGF-I，然后去除溶解度增强剂。沉淀糖浆可用于以稳定的形式储存 IGF-I，也可用于制备含有生物活性 IGF-I 的组合物。我们提供了包含这种浓缩 IGF-I 糖浆的药物组合物和试剂盒。沉淀的 IGF-I 糖浆、由 IGF-I 糖浆重组的 IGF-I、药物组合物和试剂盒可用于针对 IGF-I 反应性疾病的 IGF-I 治疗。
• Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
  申请人：Shapiro Leland

  公开号：US20060040867A1

  公开（公告）日：2006-02-23

  A novel method of treating and preventing viral infection is provided. In particular a method of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which consists of administering to a subject suffering or about to suffer from viral infection a therapeutically effective amount of a compound having a serine protease inhibitory or serpin activity. Among compounds are α 1 -antitrypsin (AAT), peptide derivatives from the carboxyterminal end of AAT, and man-made, synthetic compounds mimicking the action of such compounds. The preferred viral infections include retroviral infection such as human immunodeficiency virus (HIV) infection.

  本研究提供了一种治疗和预防病毒感染的新方法。 该方法包括向遭受或即将遭受病毒感染的受试者施用治疗有效量的具有丝氨酸蛋白酶抑制活性或丝氨酸蛋白酶活性的化合物。 这些化合物包括α 1-抗胰蛋白酶（AAT）、AAT羧基末端的肽衍生物，以及模仿此类化合物作用的人造合成化合物。 首选的病毒感染包括逆转录病毒感染，如人类免疫缺陷病毒（HIV）感染。
• COMPOSITIONS PROVIDING FOR INCREASED IGF-I SOLUBILITY
  申请人：CHIRON CORPORATION

  公开号：EP1028748B1

  公开（公告）日：2003-05-02
• NOVEL IGF-I COMPOSITION AND ITS USE
  申请人：CHIRON CORPORATION

  公开号：EP1028747A1

  公开（公告）日：2000-08-23
• Compositions providing for increased IGF-I solubility
  申请人：Chiron Corporation

  公开号：US20040209815A1

  公开（公告）日：2004-10-21

  Novel IGF-I compositions are described. The compositions include a solubilizing compound comprising a guanidinium group that provides for IGF-I compositions in which IGF-I is highly soluble at pHs of about 5.5 or greater and at refrigerated temperatures.